DK2970970T3 - Antisense-oligonukleotider til behandling af cancerstamceller - Google Patents

Antisense-oligonukleotider til behandling af cancerstamceller Download PDF

Info

Publication number
DK2970970T3
DK2970970T3 DK14770117.1T DK14770117T DK2970970T3 DK 2970970 T3 DK2970970 T3 DK 2970970T3 DK 14770117 T DK14770117 T DK 14770117T DK 2970970 T3 DK2970970 T3 DK 2970970T3
Authority
DK
Denmark
Prior art keywords
cancer
oligonucleotide
seq
sequence
dna
Prior art date
Application number
DK14770117.1T
Other languages
English (en)
Inventor
Olavarria Jaime E Villegas
Menendez Veronica A Burzio
Eriz Luis O Burzio
Original Assignee
Andes Biotechnologies Global Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Andes Biotechnologies Global Inc filed Critical Andes Biotechnologies Global Inc
Application granted granted Critical
Publication of DK2970970T3 publication Critical patent/DK2970970T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/65—MicroRNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Claims (14)

1. Oligonukleotid til anvendelse i en fremgangsmåde: (a) til undertrykkelse af metastase afen cancer hos et individ eller (b) til behandling af metastatisk cancer hos et individ; hvor oligonukleotidet er komplementært til et antisense-, ikke-kodende kimært mitochondrie-RNA- (ASncmtRNA) molekyle eller komplementært til et sense-, ikke-kodende, kimært mitochondrie-RNA- (SncmtRNA) molekyle, og hvor oligonukleotidet kan hybridisere med de kimære mitochondrie-RNA-molekylerfor et danne et stabilt dupleks, og hvor individet tidligere er behandlet for cancer med en terapi.
2. Oligonukleotid til anvendelse ifølge krav 1, hvor oligonukleotidet er tilstrækkeligt komplementært til et humant, ikke-kodende, kimært mitochondrie-RNA-molekyle, der omfatter: a. et antisense 16S mitochondrie-, ribosomalt RNA kovalent bundet ved dets 5’-ende til 3’-enden af et polynukleotid med en inverteret repeat-sekvens eller b. et sense 16S mitochondrie-, ribosomalt RNA kovalent bundet ved dets 5’-ende til 3’-enden af et polynukleotid med en inverteret repeat-sekvens.
3. Oligonukleotid til anvendelse ifølge krav 1 eller 2, hvor oligonukleotidet er komplementært til ASncmtRNA-molekylet kodet for af en nukleotidsekvens valgt fra gruppen bestående af SEQ ID NO: 4, SEQ ID NO: 5 og SEQ ID NO: 6.
4. Oligonukleotid til anvendelse ifølge krav 1 eller 2, hvor oligonukleotidet er mindst 85 % komplementært til ASncmtRNA-molekylet kodet for af en nukleotidsekvens valgt fra gruppen bestående af SEQ ID NO: 4, SEQ ID NO: 5 og SEQ ID NO: 6.
5. Oligonukleotid til anvendelse ifølge et hvilket som helst af kravene 1 til 4, hvor det ene eller flere oligonukleotid omfatter en nukleotidsekvens valgt fra gruppen bestående af SEQ ID NO: 7-198.
6. Oligonukleotid til anvendelse ifølge et hvilket som helst af kravene 1 til 5, hvor oligonukleotidet administreres i kombination med mindst ét anticancermiddel; eventuelt hvor det mindst ene anticancermiddel er valgt fra gruppen bestående af remicad, docetaxel, celecoxib, melphalan, dexamethason, steroider, gemcitabin, cisplatinum, temozolomid, etoposid, cyclophosphamid, temodar, carboplatin, procarbazin, gliadel, tamoxifen, topotecan, methotrexat, gefitinib, taxol, taxoter, fluorouracil, leucovorin, irinotecan, xeloda, CPT-11, interferon alpha, pegyleret interferon alpha, capecitabin, cisplatin, thiotepa, fludarabin, carboplatin, liposomal daunorubicin, cytarabin, doxetaxol, pacilitaxel, vinblastin, IL-2, GM-CSF, dacarbazin, vinorelbin, zoledronsyre, palmitronat, biaxin, busulphan, prednison, bortezomib, bisphosphonat, arsentrioxid, vineristin, doxorubicin, paclitaxel, ganciclovir, adriamycin, estrainustinnatriumphosphat, sulindac og etoposid.
7. Oligonukleotid til anvendelse ifølge krav 6, hvor oligonukleotidet og det mindst ene anti-cancermiddel admininistreres sekventielt eller samtidigt.
8. Oligonukleotid til anvendelse ifølge et hvilket som helst af kravene 1 til 7, hvor oligonukleotidet administreres i kombination med: (a) en stråleterapi; (b) kirurgi; (c) en allogen stamcelletransplantationsterapi; og/eller (d) en autolog stamcelletransplantationsterapi.
9. Oligonukleotid til anvendelse ifølge et hvilket som helst af kravene 1 til 8, hvor individet tidligere er behandlet for cancer med en terapi, der omfatter kemoterapi, stråleterapi, kirurgi eller kombinationer deraf.
10. Oligonukleotid til anvendelse ifølge et hvilket som helst af kravene 1 til 9, hvor canceren eller den metastatiske cancer hos individet vendte tilbage efter behandling med ét eller flere af bortezomib, cyclophosphamid, dexamethason, doxorubicin, interferon-alpha, lenalidomid, melphalan, pegyleret interferon-alpha, prednison, thalidomid og vineristin.
11. Oligonukleotid til anvendelse ifølge et hvilket som helst af kravene 1 til 10, hvor canceren er en solid cancer; eventuelt hvor den solide cancer er blærecancer, hjernecancer, brystcancer, cervixcancer, coloncancer, endometriecancer, øsofoguscancer, gastrisk cancer, lever- og galdevejscancer, lungecancer, melanom, oral cancer, ovariecancer, pankreascancer, pharynx cancer, prostatacancer, renal cancer, testiscancer eller thyroideacancer.
12. Oligonukleotid til anvendelse ifølge et hvilket som helst af kravene 1 til 10, hvor canceren er en ikke-solid cancer; eventuelt hvor den ikke-solide cancer er multipelt myelom, leukæmi eller lymfom.
13. Oligonukleotid til anvendelse ifølge et hvilket som helst af kravene 1 til 12, hvor oligonukleotidet reducerer antallet af cancerstamceller hos individet sammenlignet med et individ, der ikke har fået administreret oligonukleotidet.
14. Oligonukleotid til anvendelse ifølge et hvilket som helst af kravene 1 til 13, hvor oligonukleotidet hæmmer tumorvækst og/eller metastase hos individet sammenlignet med et individ, der ikke har fået administreret oligonukleotidet.
DK14770117.1T 2013-03-14 2014-03-14 Antisense-oligonukleotider til behandling af cancerstamceller DK2970970T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361785269P 2013-03-14 2013-03-14
US201361790072P 2013-03-15 2013-03-15
US201461937438P 2014-02-07 2014-02-07
PCT/US2014/029606 WO2014153209A1 (en) 2013-03-14 2014-03-14 Antisense oligonucletotides for treatment of cancer stem cells

Publications (1)

Publication Number Publication Date
DK2970970T3 true DK2970970T3 (da) 2019-02-11

Family

ID=51581450

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14770117.1T DK2970970T3 (da) 2013-03-14 2014-03-14 Antisense-oligonukleotider til behandling af cancerstamceller

Country Status (14)

Country Link
US (3) US9862944B2 (da)
EP (1) EP2970970B1 (da)
JP (1) JP6313419B2 (da)
CN (2) CN105229150A (da)
BR (1) BR112015022308A8 (da)
CA (1) CA2906198C (da)
CL (1) CL2015002612A1 (da)
DK (1) DK2970970T3 (da)
ES (1) ES2708650T3 (da)
HK (1) HK1220482A1 (da)
HU (1) HUE042738T2 (da)
MX (1) MX359337B (da)
PL (1) PL2970970T3 (da)
WO (1) WO2014153209A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10066269B2 (en) 2013-03-14 2018-09-04 Andes Biotechnologies Global, Inc. Methods for detecting and treating multiple myeloma
EP2970970B1 (en) 2013-03-14 2018-12-12 Andes Biotechnologies Global, Inc. Antisense oligonucleotides for treatment of cancer stem cells
WO2019103578A1 (ko) * 2017-11-27 2019-05-31 (주)프로스테믹스 올리고뉴클레오티드 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물
JP7434359B2 (ja) * 2019-04-11 2024-02-20 北京基石生命科技有限公司 胃がん及び胆嚢・胆管がん初代細胞を培養する方法及び補助試薬
CN113893261B (zh) * 2021-06-22 2023-01-13 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） circITGB6-ASO与铂类化疗药物联合使用在制备治疗卵巢癌的药物中的应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US5550111A (en) 1984-07-11 1996-08-27 Temple University-Of The Commonwealth System Of Higher Education Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
ATE113059T1 (de) 1987-06-24 1994-11-15 Florey Howard Inst Nukleosid-derivate.
US5194599A (en) 1988-09-23 1993-03-16 Gilead Sciences, Inc. Hydrogen phosphonodithioate compositions
US5399676A (en) 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
US5721218A (en) 1989-10-23 1998-02-24 Gilead Sciences, Inc. Oligonucleotides with inverted polarity
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5681941A (en) 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
US5321131A (en) 1990-03-08 1994-06-14 Hybridon, Inc. Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
US5623070A (en) 1990-07-27 1997-04-22 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
CA2088258C (en) 1990-07-27 2004-09-14 Phillip Dan Cook Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression
US5618704A (en) 1990-07-27 1997-04-08 Isis Pharmacueticals, Inc. Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
US5608046A (en) 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5677437A (en) 1990-07-27 1997-10-14 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
NZ239247A (en) 1990-08-03 1993-11-25 Sterling Drug Inc Oligonucleosides containing a non-phosphate inter nucleoside linkage
US5596086A (en) 1990-09-20 1997-01-21 Gilead Sciences, Inc. Modified internucleoside linkages having one nitrogen and two carbon atoms
US5672697A (en) 1991-02-08 1997-09-30 Gilead Sciences, Inc. Nucleoside 5'-methylene phosphonates
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5571799A (en) 1991-08-12 1996-11-05 Basco, Ltd. (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
US5594121A (en) 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
EP1256589A3 (en) 1991-11-26 2003-09-17 Isis Pharmaceuticals, Inc. Oligomers containing modified pyrimidines
US5484908A (en) 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
TW393513B (en) 1991-11-26 2000-06-11 Isis Pharmaceuticals Inc Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US5792608A (en) 1991-12-12 1998-08-11 Gilead Sciences, Inc. Nuclease stable and binding competent oligomers and methods for their use
US5633360A (en) 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
EP0691977B1 (en) 1993-03-31 1997-11-26 Sanofi Oligonucleotides with amide linkages replacing phosphodiester linkages
US5502177A (en) 1993-09-17 1996-03-26 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5625050A (en) 1994-03-31 1997-04-29 Amgen Inc. Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
US5646269A (en) 1994-04-28 1997-07-08 Gilead Sciences, Inc. Method for oligonucleotide analog synthesis
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
US8715645B2 (en) 1994-05-27 2014-05-06 The Regents Of The University Of Colorado Viral vectors encoding apoptosis-inducing proteins and methods for making and using the same
DE69819150T3 (de) 1997-06-06 2007-12-20 Dynavax Technologies Corp., San Diego Immunstimulierende oligonucleotide, zusammensetzungen davon, und verfahren zur verwendung davon
ES2536002T3 (es) 2003-05-21 2015-05-19 Andes Biotechnologies S.A. Marcadores para células pre-cancerígenas y cancerígenas y el método para interferir con la proliferación celular en ellas
BRPI0617657A2 (pt) 2005-10-20 2016-08-23 Tokuyama Corp método para remover ar de um fluido de revestimento contendo ar arrastado, e, aparelho de remoção de ar arrastado em um fluido de revestimento
JP5342881B2 (ja) 2006-01-27 2013-11-13 アイシス ファーマシューティカルズ， インコーポレーテッド ６−修飾された二環式核酸類似体
DK2015758T3 (da) 2006-05-05 2014-06-23 Isis Pharmaceuticals Inc Forbindelser og fremgangsmåder til modulering af ekspression af apob
WO2009026576A1 (en) 2007-08-23 2009-02-26 Keren Pharmaceuticals Targeting rna with external guide sequences
AU2008327541B2 (en) 2007-11-20 2014-02-27 Hopitaux Universitaires De Geneve Methods for identifying, purifying and enriching immature or stem cancer-initiating cells from tumors and use thereof
ES2646097T3 (es) 2009-08-27 2017-12-12 Idera Pharmaceuticals, Inc. Composición para inhibir la expresión de genes y sus usos
US10066269B2 (en) 2013-03-14 2018-09-04 Andes Biotechnologies Global, Inc. Methods for detecting and treating multiple myeloma
EP2970970B1 (en) 2013-03-14 2018-12-12 Andes Biotechnologies Global, Inc. Antisense oligonucleotides for treatment of cancer stem cells

Also Published As

Publication number Publication date
US10457943B2 (en) 2019-10-29
BR112015022308A8 (pt) 2018-01-23
EP2970970A4 (en) 2016-10-19
US20200239885A1 (en) 2020-07-30
CN105229150A (zh) 2016-01-06
US11319535B2 (en) 2022-05-03
US20180171335A1 (en) 2018-06-21
CA2906198A1 (en) 2014-09-25
WO2014153209A8 (en) 2015-02-26
WO2014153209A1 (en) 2014-09-25
ES2708650T3 (es) 2019-04-10
MX359337B (es) 2018-07-09
BR112015022308A2 (pt) 2017-10-10
HUE042738T2 (hu) 2019-07-29
US9862944B2 (en) 2018-01-09
CN115518073A (zh) 2022-12-27
MX2015012063A (es) 2016-04-06
JP2016519084A (ja) 2016-06-30
EP2970970A1 (en) 2016-01-20
CA2906198C (en) 2022-11-29
JP6313419B2 (ja) 2018-04-18
HK1220482A1 (zh) 2017-05-05
EP2970970B1 (en) 2018-12-12
CL2015002612A1 (es) 2016-08-26
US20160138015A1 (en) 2016-05-19
PL2970970T3 (pl) 2019-06-28

Similar Documents

Publication Publication Date Title
US11319535B2 (en) Antisense oligonucleotides for treatment of cancer stem cells
JP2019501670A (ja) 改変された腫瘍溶解性ウイルス
BR112020018364A2 (pt) Sistemas e métodos para o tratamento de hemoglobinopatias
US20080255065A1 (en) Small Interfering Rna Molecules Against Ribonucleotide Reductase and Uses Thereof
JP2012056961A (ja) リボヌクレオチド還元酵素ｒ２を指向するアンチセンスオリゴヌクレオチドおよび癌の治療におけるこれらの使用
US20170016002A1 (en) Method of Treating Cancer by Inhibition of DNA Repair Proteins
CN106574241A (zh) 癌症免疫疗法组合物和方法
US20230242913A1 (en) Sting-dependent activators for treatment of disease
Guo et al. siRNA-mediated inhibition of hTERT enhances chemosensitivity of hepatocellular carcinoma
US20230040280A1 (en) Antisense oligonucleotides for treatment of cancer stem cells
US10907159B2 (en) Methods of treating cancer by inhibition of DNA repair proteins using antisense based therapies
EP2970364B1 (en) Methods for detecting and treating multiple myeloma
US20170183650A1 (en) Pharmaceutical compositions comprising rna and use for treating cancer
Caruso et al. New therapeutic strategies in gliomas treatment
US20220162617A1 (en) Methods of modulating slc7a11 pre-mrna transcripts for diseases and conditions associated with expression of slc7a11
WO2023212572A2 (en) Long non-coding rna 122 (lnc122) for treating cancer
KR20140059002A (ko) 다제내성 종양 치료를 위한 항암제 및 치료방법